What is Leerink Partnrs’ Forecast for ITOS Q4 Earnings?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Investment analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for shares of iTeos Therapeutics in a note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings per share of ($0.38) for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for iTeos Therapeutics’ FY2029 earnings at ($1.78) EPS.

Several other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. cut shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $15.00 to $8.00 in a research note on Tuesday. Wells Fargo & Company reaffirmed an “overweight” rating and set a $13.00 target price (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday. Raymond James set a $12.00 target price on shares of iTeos Therapeutics in a research note on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday. Finally, Wedbush reissued an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, iTeos Therapeutics presently has a consensus rating of “Hold” and an average target price of $17.86.

iTeos Therapeutics Stock Performance

ITOS opened at $7.81 on Friday. The stock has a market capitalization of $298.92 million, a price-to-earnings ratio of -2.48 and a beta of 1.39. The company has a fifty day moving average of $6.61 and a 200 day moving average of $7.42. iTeos Therapeutics has a fifty-two week low of $4.80 and a fifty-two week high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14.

Insider Transactions at iTeos Therapeutics

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider now owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. This trade represents a 23.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now owns 3,452,797 shares of the company’s stock, valued at $27,829,543.82. This trade represents a 23.01% decrease in their position. The disclosure for this sale can be found here. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ITOS. BVF Inc. IL bought a new stake in iTeos Therapeutics during the 4th quarter valued at about $17,856,000. JPMorgan Chase & Co. lifted its holdings in iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock valued at $15,888,000 after buying an additional 1,601,477 shares in the last quarter. RA Capital Management L.P. lifted its holdings in iTeos Therapeutics by 74.4% during the 1st quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company’s stock valued at $21,785,000 after buying an additional 1,556,798 shares in the last quarter. Boxer Capital Management LLC bought a new stake in iTeos Therapeutics during the 4th quarter valued at about $7,272,000. Finally, 683 Capital Management LLC lifted its holdings in iTeos Therapeutics by 90.6% during the 1st quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company’s stock valued at $10,448,000 after buying an additional 831,883 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.